KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Acadia Pharmaceuticals (ACAD) Shares Outstanding (Weighted Average) (2016 - 2025)

Acadia Pharmaceuticals (ACAD) has 16 years of Shares Outstanding (Weighted Average) data on record, last reported at $168.4 million in Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) rose 1.59% year-over-year to $168.4 million; the TTM value through Dec 2025 reached $168.4 million, up 1.59%, while the annual FY2025 figure was $168.4 million, 1.59% up from the prior year.
  • Shares Outstanding (Weighted Average) reached $168.4 million in Q4 2025 per ACAD's latest filing, roughly flat from $168.8 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $168.8 million in Q3 2025 and bottomed at $160217.0 in Q2 2021.
  • Average Shares Outstanding (Weighted Average) over 5 years is $115.3 million, with a median of $162.7 million recorded in 2023.
  • Peak YoY movement for Shares Outstanding (Weighted Average): skyrocketed 101542.53% in 2023, then tumbled 99.9% in 2024.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $160493.0 in 2021, then skyrocketed by 100641.47% to $161.7 million in 2022, then grew by 1.32% to $163.8 million in 2023, then rose by 1.16% to $165.7 million in 2024, then rose by 1.59% to $168.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding (Weighted Average) were $168.4 million in Q4 2025, $168.8 million in Q3 2025, and $167.8 million in Q2 2025.